ALL-097 Elevated CD83 in Adult Acute Lymphoblastic Leukemia Associated With Poor Clinical Outcome

Abstract

CD83 is expressed by mature dendritic cells and activated lymphocytes but not by other peripheral blood cells. Some tumor cells have high expression of CD83 on the cell surface, such as Hodgkin lymphomas (HLs), diffuse large B-cell lymphoma, adult acute lymphoblastic leukemia (ALL), gastric extra-nodal marginal zone lymphomas, and lung cancer cells. To determine the prognostic role of CD83 in adult ALL and correlated it with clinical outcome. Prospective study. The patients were followed up for 12 months. Clinical Hematology and Oncology Unit, Internal Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt. 60 subjects (40 newly diagnosed adult ALL patients and 20 age- and sex-matched healthy controls. We analyzed CD83 expression by flow cytometry. Cases have been followed up for one year after enrollment into the study. To measure CD83 in newly diagnosed ALL patients and correlate its level with clinical outcome and treatment response. ALL patients exhibited a statistically significant increase in CD83 expression on their lymphoblast compared to the control group median 19.5% (IQR 5.4-48.15%) vs 7% (IQR 6.1-8.5%), respectively. Based on CD83 expression on BM lymphoblast, patients were divided into two groups: a group with high CD83 (≥9.8%) and the other with normal CD83 expression (<9.8%) compared to the control group. The median (IQR) of the overall survival and disease-free survival was longer than those normally expressed CD83 versus those with higher expression [180days (IQR 60-240) and 105 days (IQR 30-160) vs 80 days (IQR 60-240) and 51 days (IQR 22-150), respectively]. We concluded that elevated serum CD83 at diagnosis can be used as a prognostic marker and predictor of disease response to chemotherapy in patients with ALL and is associated with inferior overall and disease-free survival.